Principal Financial Group’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.6M Buy
205,456
+41,677
+25% +$2.71M 0.01% 1247
2025
Q4
$13.1M Buy
163,779
+15,489
+10% +$1.04M 0.01% 1136
2025
Q3
$7.23M Sell
148,290
-19,413
-12% -$1.2M ﹤0.01% 1449
2025
Q2
$12.5M Buy
167,703
+8,809
+6% +$583K 0.01% 1127
2025
Q1
$10.1M Buy
158,894
+2,160
+1% +$147K 0.01% 1255
2024
Q4
$12.2M Buy
156,734
+1,475
+1% +$118K 0.01% 1174
2024
Q3
$12.5M Sell
155,259
-37,433
-19% -$3.02M 0.01% 1134
2024
Q2
$15.9M Sell
192,692
-18,985
-9% -$1.67M 0.01% 995
2024
Q1
$18.1M Buy
211,677
+7,713
+4% +$605K 0.01% 978
2023
Q4
$17.4M Buy
203,964
+4,604
+2% +$398K 0.01% 958
2023
Q3
$17.9M Buy
199,360
+844
+0.4% +$75.4K 0.01% 874
2023
Q2
$16.9M Sell
198,516
-8,928
-4% -$755K 0.01% 942
2023
Q1
$17.2M Sell
207,444
-1,361
-0.7% -$110K 0.01% 937
2022
Q4
$16.4M Sell
208,805
-4,566
-2% -$367K 0.01% 951
2022
Q3
$15.8M Sell
213,371
-23,527
-10% -$1.69M 0.01% 923
2022
Q2
$15.4M Buy
236,898
+54,583
+30% +$3.23M 0.01% 1012
2022
Q1
$11.5M Sell
182,315
-1,282
-0.7% -$69.7K 0.01% 1285
2021
Q4
$9.74M Buy
183,597
+2,807
+2% +$171K 0.01% 1419
2021
Q3
$12.8M Buy
180,790
+319
+0.2% +$20.1K 0.01% 1273
2021
Q2
$12M Sell
180,471
-200,077
-53% -$14.2M 0.01% 1333
2021
Q1
$42.2M Buy
380,548
+227,285
+148% +$28.1M 0.03% 489
2020
Q4
$18.2M Sell
153,263
-521
-0.3% -$56.1K 0.01% 837
2020
Q3
$13.4M Sell
153,784
-4,993
-3% -$436K 0.01% 892
2020
Q2
$14.2M Buy
158,777
+927
+0.6% +$93.6K 0.01% 835
2020
Q1
$15.7M Sell
157,850
-65,443
-29% -$7.1M 0.02% 654
2019
Q4
$25.7M Sell
223,293
-1,564
-0.7% -$189K 0.02% 632
2019
Q3
$28.4M Sell
224,857
-4,447
-2% -$564K 0.03% 571
2019
Q2
$27.6M Sell
229,304
-7,658
-3% -$753K 0.02% 587
2019
Q1
$20.7M Sell
236,962
-969
-0.4% -$88.1K 0.02% 745
2018
Q4
$23.8M Sell
237,931
-22,347
-9% -$2.35M 0.03% 612
2018
Q3
$29.8M Buy
260,278
+4,124
+2% +$427K 0.03% 610
2018
Q2
$23M Sell
256,154
-190,294
-43% -$16.1M 0.02% 737
2018
Q1
$32.7M Buy
446,448
+16,073
+4% +$1.1M 0.03% 544
2017
Q4
$25M Sell
430,375
-638
-0.1% -$33.6K 0.02% 676
2017
Q3
$19.3M Sell
431,013
-3,377
-0.8% -$140K 0.02% 797
2017
Q2
$17.2M Buy
434,390
+28,812
+7% +$1.18M 0.02% 868
2017
Q1
$16.5M Buy
405,578
+15,369
+4% +$600K 0.02% 855
2016
Q4
$15.7M Buy
390,209
+10,376
+3% +$391K 0.02% 856
2016
Q3
$13.8M Buy
379,833
+20,313
+6% +$697K 0.02% 904
2016
Q2
$10.4M Buy
359,520
+961
+0.3% +$29K 0.01% 1015
2016
Q1
$12.5M Buy
358,559
+14,454
+4% +$467K 0.02% 845
2015
Q4
$11.1M Buy
344,105
+16,768
+5% +$544K 0.02% 888
2015
Q3
$10.6M Buy
327,337
+3,627
+1% +$136K 0.02% 885
2015
Q2
$13.4M Sell
323,710
-5,104
-2% -$215K 0.02% 794
2015
Q1
$14.8M Buy
328,814
+8,935
+3% +$374K 0.02% 700
2014
Q4
$12M Sell
319,879
-1,191
-0.4% -$43.6K 0.02% 827
2014
Q3
$11.2M Sell
321,070
-7,463
-2% -$266K 0.02% 821
2014
Q2
$11.6M Sell
328,533
-1,946
-0.6% -$65K 0.02% 841
2014
Q1
$10.8M Buy
330,479
+13,696
+4% +$523K 0.02% 879
2013
Q4
$13.3M Buy
316,783
+19,500
+7% +$802K 0.02% 705
2013
Q3
$11.9M Buy
297,283
+9,887
+3% +$415K 0.02% 722
2013
Q2
$11.9M Buy
+287,396
New +$11.6M 0.03% 664

Other funds holding HAE

Principal Financial Group's HAE Position: Q1 2026 in Review

Principal Financial Group increased its Haemonetics (HAE) stake by 25% in Q1 2026, buying an estimated $2.71M and bringing the position to 205,456 shares worth $11.6M. The position accounts for 0.01% of the portfolio, ranked #1247.

Principal Financial Group first reported a position in HAE in Q2 2013 and has held it in 52 quarters since. The position peaked at $42.2M in Q1 2021. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Principal Financial Group held 205,456 shares of Haemonetics worth $11.6M as of Q1 2026.
  • Principal Financial Group bought 41,677 Haemonetics shares in Q1 2026, an estimated $2.71M.
  • Haemonetics made up 0.01% of Principal Financial Group's portfolio in Q1 2026, its #1247 holding.
  • Principal Financial Group first reported a position in Haemonetics in Q2 2013 and has held it in 52 quarters since.
  • Principal Financial Group's Haemonetics position peaked at $42.2M in Q1 2021.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Principal Financial Group's 13F filing for Q1 2026, filed 4 May 2026.